Renal cell carcinoma: genes and variants
Explore variant evidence for Renal cell carcinoma across 19 analyzed proteins (MET, BRAF, CSF1R, CTLA4, EPAS1 and 14 more). Linked ClinVar records include 4 pathogenic or likely pathogenic variants, 1,353 variants of uncertain significance and 388 with conflicting classifications.
Coverage includes proteins already analyzed in CATVariant, not every gene involved in this condition. Database links are associations, not an assessment of clinical gene–disease validity. Computable evidence prioritizes variants for expert review and does not reclassify them. Counts refer to the selected disease label.
Data updated 2026-10-21. Automated aggregation, not a clinical review date.
Download variant evidence (CSV)
Genes linked to Renal cell carcinoma
MET: Hepatocyte growth factor receptor
Hepatocyte-growth-factor signaling through this pathway promotes cell survival, proliferation, motility, and invasive growth during development and tissue repair. Exon 14 skipping, amplification, activating mutations, or fusions can drive cancer and create actionable therapeutic dependencies.
4 ClinVar pathogenic / likely pathogenic and 1,741 uncertain variants in MET have source records linked to Renal cell carcinoma. Association strength is not clinical gene validity.
BRAF: Serine/threonine-protein kinase B-raf
It relays activated RAS signals through MEK and ERK to control proliferation, differentiation, and survival. Activating variants, especially V600E, drive melanoma and several other cancers and create sensitivity to pathway-directed therapies.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in BRAF have source records linked to Renal cell carcinoma. Association strength is not clinical gene validity.
CSF1R: Macrophage colony-stimulating factor 1 receptor
Signals from CSF1 and IL-34 through this pathway are required for development, survival, and function of macrophages and microglia. Pathogenic variants can cause adult-onset leukoencephalopathy with cognitive, psychiatric, and motor deterioration.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in CSF1R have source records linked to Renal cell carcinoma. Association strength is not clinical gene validity.
CTLA4: Cytotoxic T-lymphocyte protein 4
It restrains T-cell activation by competing with CD28 for CD80 and CD86 and by delivering inhibitory signals after immune activation. Haploinsufficiency causes immune dysregulation with autoimmunity and lymphoproliferation, while therapeutic blockade enhances antitumor immunity.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in CTLA4 have source records linked to Renal cell carcinoma. Association strength is not clinical gene validity.
EPAS1: Endothelial PAS domain-containing protein 1
When stabilized by hypoxia, it activates hypoxia-responsive genes controlling erythropoiesis, angiogenesis, iron metabolism, and cellular adaptation to low oxygen. Activating variants can cause familial erythrocytosis, while somatic dysregulation is central to clear-cell renal carcinoma and some paragangliomas.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in EPAS1 have source records linked to Renal cell carcinoma. Association strength is not clinical gene validity.
FGFR1: Fibroblast growth factor receptor 1
Its fibroblast-growth-factor signaling controls proliferation, differentiation, migration, and developmental patterning in many tissues. Germline pathogenic variants can cause hypogonadotropic hypogonadism or craniosynostosis syndromes, while fusions and other activating alterations drive selected cancers.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in FGFR1 have source records linked to Renal cell carcinoma. Association strength is not clinical gene validity.
FGFR3: Fibroblast growth factor receptor 3
It normally restrains growth-plate chondrocyte proliferation while regulating multiple developmental pathways. Activating germline variants cause achondroplasia and related skeletal dysplasias, while somatic activating alterations are common in bladder cancer and some other tumors.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in FGFR3 have source records linked to Renal cell carcinoma. Association strength is not clinical gene validity.
FLT3: Receptor-type tyrosine-protein kinase FLT3
Its signaling supports survival and expansion of early hematopoietic progenitors. Internal tandem duplications and kinase-domain mutations produce constitutive activity in acute myeloid leukemia and are important prognostic markers and therapeutic targets.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in FLT3 have source records linked to Renal cell carcinoma. Association strength is not clinical gene validity.
IL2RA: Interleukin-2 receptor subunit alpha
It contributes to the high-affinity IL-2 receptor on activated T cells and regulatory T cells, supporting lymphocyte proliferation and immune tolerance. Loss-of-function variants can cause immunodeficiency with autoimmunity, while abnormal expression is therapeutically targeted in selected immune disorders.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in IL2RA have source records linked to Renal cell carcinoma. Association strength is not clinical gene validity.
IL2RB: Interleukin-2 receptor subunit beta
It transmits signals from IL-2 and IL-15 that are essential for regulatory T cells, natural-killer cells, and memory lymphocytes. Biallelic pathogenic variants can cause combined immunodeficiency with prominent autoimmunity and defective immune regulation.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in IL2RB have source records linked to Renal cell carcinoma. Association strength is not clinical gene validity.
IL2RG: Cytokine receptor common subunit gamma
It is the shared signaling chain used by receptors for several interleukins required for lymphocyte development and survival. Loss-of-function variants cause X-linked severe combined immunodeficiency with profound T-cell and natural-killer-cell deficiency.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in IL2RG have source records linked to Renal cell carcinoma. Association strength is not clinical gene validity.
ITK: Tyrosine-protein kinase ITK/TSK
A Tec-family kinase that relays T-cell receptor signals needed for T-cell development and activation. Deficiency can cause combined immunodeficiency.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in ITK have source records linked to Renal cell carcinoma. Association strength is not clinical gene validity.
KIT: Mast/stem cell growth factor receptor Kit
Stem-cell-factor signaling through this pathway supports hematopoietic progenitors, mast cells, melanocytes, and germ cells. Activating variants drive gastrointestinal stromal tumors, systemic mastocytosis, and other malignancies, whereas loss-of-function variants can cause piebaldism.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in KIT have source records linked to Renal cell carcinoma. Association strength is not clinical gene validity.
LCK: Tyrosine-protein kinase Lck
It phosphorylates the earliest signaling components downstream of the T-cell receptor and CD4 or CD8 coreceptors, making it essential for T-cell development and activation. Severe loss-of-function can cause combined immunodeficiency, while aberrant activity contributes to lymphoid malignancy.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in LCK have source records linked to Renal cell carcinoma. Association strength is not clinical gene validity.
PDCD1: Programmed cell death protein 1
PDCD1 is an inhibitory receptor on activated T cells that binds PD-L1 and PD-L2. Its signaling helps maintain immune tolerance by restraining T-cell activation, making the protein important in autoimmunity and cancer immunotherapy.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in PDCD1 have source records linked to Renal cell carcinoma. Association strength is not clinical gene validity.
PDGFRA: Platelet-derived growth factor receptor alpha
PDGF signaling through this pathway promotes proliferation, survival, and migration of mesenchymal progenitors. Activating mutations or fusions drive gastrointestinal stromal tumors and selected hematologic and solid malignancies and can create kinase-inhibitor sensitivity.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in PDGFRA have source records linked to Renal cell carcinoma. Association strength is not clinical gene validity.
PDGFRB: Platelet-derived growth factor receptor beta
Its signaling supports pericytes, vascular smooth-muscle cells, and other mesenchymal lineages during growth and tissue repair. Oncogenic fusions drive myeloid neoplasms, while germline activating or loss-of-function variants can cause developmental and vascular disorders.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in PDGFRB have source records linked to Renal cell carcinoma. Association strength is not clinical gene validity.
RET: Proto-oncogene tyrosine-protein kinase receptor Ret
Its activation by GDNF-family ligands guides development of the enteric nervous system, kidney, and other tissues. Activating variants cause multiple endocrine neoplasia type 2 and can drive cancer, whereas loss-of-function variants are an important cause of Hirschsprung disease.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in RET have source records linked to Renal cell carcinoma. Association strength is not clinical gene validity.
VHL: von Hippel-Lindau disease tumor suppressor
It targets hydroxylated HIF-alpha proteins for ubiquitin-mediated degradation when oxygen is sufficient, keeping hypoxia-response programs suppressed. Loss of function stabilizes HIF signaling and causes von Hippel-Lindau tumor-predisposition syndrome while also driving most clear-cell renal carcinomas.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in VHL have source records linked to Renal cell carcinoma. Association strength is not clinical gene validity.
ClinVar pathogenic and likely pathogenic variants linked to Renal cell carcinoma
| Variant | Position | Protein part | Clinical label |
|---|---|---|---|
| MET M1131T | 1131 | Protein kinase | Pathogenic / likely pathogenic (★★) |
| MET V1092I | 1092 | Protein kinase | Pathogenic / likely pathogenic (★★) |
| MET H1094R | 1094 | Protein kinase | Pathogenic / likely pathogenic (★★) |
| MET V1220I | 1220 | Protein kinase | Pathogenic / likely pathogenic (★★) |
Diseases related to Renal cell carcinoma
- Non-small cell lung carcinoma, also linked to BRAF, CTLA4, FGFR1, MET and 4 more
- Colorectal cancer, also linked to BRAF, FGFR1, FGFR3, KIT and 3 more
- Hepatocellular carcinoma, also linked to BRAF, CTLA4, FLT3, KIT and 3 more
- Gastrointestinal stromal tumor, also linked to CSF1R, FLT3, KIT, PDGFRA and 2 more
- Acute myeloid leukemia, also linked to FLT3, KIT, PDGFRA and PDGFRB
- Acute lymphoid leukemia, also linked to FLT3, KIT, LCK and PDGFRB
- Ovarian cancer, also linked to KIT, PDGFRA and RET
- Idiopathic pulmonary fibrosis, also linked to FGFR1, PDGFRA and PDGFRB
- Chronic myeloid leukemia, also linked to KIT, LCK and PDGFRB
- Melanoma, also linked to BRAF, CTLA4 and PDCD1
- Multiple sclerosis, also linked to IL2RA, IL2RB and IL2RG
- Interstitial lung disease, also linked to FGFR1, PDGFRA and PDGFRB
Frequently asked questions
Which genes have records linked to Renal cell carcinoma?
This view contains 19 analyzed proteins: MET, BRAF, CSF1R, CTLA4, EPAS1 and 14 more. Links come from clinical records and association databases. They do not imply that every listed gene is a validated cause, and missing genes may not yet be analyzed.
What do the clinical classifications mean?
Linked records include 4 pathogenic or likely pathogenic variants, 1,353 variants of uncertain significance and 388 with conflicting classifications. Labels summarize source records; multi-condition records may not make a separate assertion for this disease. Check the original record and review status.
Does the evidence score change a VUS classification?
No. 0 VUS or conflicting variants reach the likely-pathogenic points range on the computable criteria available here. This is a research prioritization signal, not a clinical classification. Patient, family and other required evidence may be missing.
Can I download the variant evidence?
Download the CSV for all 1,758 variants in the selected disease scope, including clinical labels, review status, evidence criteria, predictor scores, functional measurements and population frequency where available.
About this data
Variant–disease links come from ClinVar, Open Targets and UniProt, pooled from eligible public CATVariant analyses of each human protein. Evidence scores use the ACMG/AMP Bayesian points scale with computable criteria only (position among known disease variants, rarity in gnomAD, calibrated predictors, deep mutational scanning); there is no family or patient data, so they prioritise variants for expert review and never classify them.
Download every variant as CSV · Browse all diseases · Methods · About the Center